Drug major Ranbaxy Laboratories Ltd today posted consolidated net loss of Rs 73.6 crore for the fourth quarter ended March 31, 2014
Ranbaxy Laboratories had posted net profit of Rs 125.75 crore during the January-March quarter of the previous fiscal, 2012-13.
Ranbaxy’s net sales during Q4, 2013-14 grew marginally by 1.03 per cent to Rs 2,436.1 crore, as against Rs 2,411.1 crore in the year-ago period.
- Varun Gandhi Under Attack Over Defence Deals: Here’s How
- This Diwali, Let Blind Students Brighten Up your Homes With Candles & Diyas
- CBI Files Supplementary Chargesheet In Sheena Bora Murder Case
- Soha Ali Khan And Vir Das Starrer 31st October Audience Reaction
- Sahara Chief Subrata Roy’s Parole Extended Till November 28
- Simple Tips To Secure Your Debit Card From Fraudsters
- New Zealand & India Team Being Welcomed In Chandigarh
- Mumbai Call Centre Scam: All You Need To Know
- Jammu Kashmir Chief Minister Mehbooba Mufti Appeals To Police: Here’s What She Said
- Shocker From Ahmedabad: Find Out What Happened
- Bigg Boss 10 Day 3 Review: Celebs Fail To Do Well in First Task
- Airtel Offers 10GB Data At Rs 259 For New 4G Smartphone Users
- Aamir Khan Starrer Dangal’s Trailer Launched: First Impressions
- TMC Supporters Attack BJP Leader Babul Supriyo
- Sri Lankan Navy Apprehends 20 Indian Fishermen
During the quarter, the company recorded inventory and other costs write-off and goodwill impairment write-off of Rs 15.9 crore and Rs 43.8 crore respectively.
Ranbaxy Laboratories CEO and Managing Director Arun Sawhney said: “Despite multiple challenges, Ranbaxy met its sales guidance and continued to build on its strengths. At the same time we continued to work closely with regulatory agencies to address their concerns.”
Ranbaxy scrip closed at Rs 464.50, down 1.06 per cent, on the BSE.
On April 7, Sun Pharmaceutical announced it will fully acquire the troubled Ranbaxy Laboratories in an all-stock transaction with a total equity value of USD 3.2 billion.
Under the agreement, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.
The combination of Sun Pharma and Ranbaxy will create the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.
Imports of Ranbaxy products from all its four plants in India have been banned by American regulator USFDA for violations of manufacturing norms. In 2013, the company agreed to pay USD 500 million fine after pleading guilty to felony charges over manufacturing and distribution of adulterated drugs in the US.